Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
Mayne Pharma Group Limited has announced the cessation of 5,503 performance rights due to unmet conditions, as of October 28, 2025. This announcement may impact the company’s operational strategy and stakeholder interests, reflecting a potential shift in how performance incentives are managed within the organization.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company is known for its commitment to providing high-quality medications and has a significant presence in various international markets.
Average Trading Volume: 367,880
Technical Sentiment Signal: Buy
Current Market Cap: A$501.3M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.